21.43  -0.29 (-1.34%)		05-12 16:00
Open: 21.72 High: 22.02 Volume: 8,355,116		Pre. Close: 21.72 Low: 21.175 Market Cap: 10,703(M)

Short term
Mid term
Targets	6-month :	28.42	1-year :	30.7
Resists	First :	24.33	Second :	26.29
Pivot price	22.73
Supports	First :	21.17	Second :	17.61
MAs	MA(5) :	23.39	MA(20) :	22.86
	MA(100) :	23.82	MA(250) :	20.22
MACD	MACD :	-0.3	Signal :	-0.2
%K %D	K(14,3) :	16.8	D(3) :	37.6
RSI	RSI(14): 41.3
52-week	High :	27.71	Low :	12.39

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ELAN ] has closed above bottom band by 21.1%. Bollinger Bands are 65.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	22.05 - 22.21	22.21 - 22.33
Low:	20.78 - 20.98	20.98 - 21.14
Close:	21.14 - 21.42	21.42 - 21.64

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Fri, 08 May 2026
ELAN SEC Filings - Elanco Animal Health 10-K, 10-Q, 8-K Forms - Stock Titan

Fri, 08 May 2026
Elanco Animal Health Q1 2026: EPS Tops Estimates — Deep Dive - AlphaStreet

Fri, 08 May 2026
Results: Elanco Animal Health Incorporated Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st

Thu, 07 May 2026
Elanco Animal Health Moves Higher On Earnings Strength And Product Momentum - Sahm

Wed, 06 May 2026
Elanco Animal Health Incorporated 2026 Q1 - Results - Earnings Call Presentation (NYSE:ELAN) 2026-05-06 - Seeking Alpha

Wed, 06 May 2026
elan-20260331 - SEC.gov

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	499 (M)
Shares Float	493 (M)
Held by Insiders	1.1 (%)
Held by Institutions	109 (%)
Shares Short	24,560 (K)
Shares Short P.Month	17,140 (K)

EPS	-0.47
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	13.17
Profit Margin	-5 %
Operating Margin	2.2 %
Return on Assets (ttm)	1.2 %
Return on Equity (ttm)	-3.7 %
Qtrly Rev. Growth	12.1 %
Gross Profit (p.s.)	5.18
Sales Per Share	9.43
EBITDA (p.s.)	1.81
Qtrly Earnings Growth	0 %
Operating Cash Flow	560 (M)
Levered Free Cash Flow	560 (M)

PE Ratio	-45.6
PEG Ratio	3.7
Price to Book value	1.62
Price to Sales	2.27
Price to Cash Flow	19.11

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.